

Memorandum

Date: Wednesday, May 18, 2022
To: Maui Health Providers and Community Physicians
From: Maui Health Physician Leadership
Subject: **COVID-19 Outpatient Therapies**

Dear Colleagues,

On Wednesday May 11, 2022, the Hawaii Department of Health announced general availability of [outpatient treatment therapeutics for COVID-19](#).

Most Maui pharmacies carry oral medications (Paxlovid and Molnupiravir) and are able to dispense these to patients via [CDC Test To Treat \(hhs.gov\) program](#).

When prescribing **oral therapy** for COVID-19, consider the following:

1. Availability of outpatient Paxlovid and Molnupiravir varies. The [Test-to-Treat](#) website does not reflect actual pharmacy supply levels. **Call pharmacy to confirm availability.**
2. Both oral options (Paxlovid and Molnupiravir) must be **started within 5 days of onset of symptoms**. They can only be used for those **aged ≥ 12 years** and **weighing ≥ 40 kg**.
3. Patients must be **symptomatic, with mild-moderate disease (not requiring oxygen), and [with risk factors for severe disease](#)**.
4. **Paxlovid has multiple drug interactions.**
 - a. It cannot be used if patient is taking amiodarone, clopidogrel, rivaroxaban, and multiple other medications (*see tables below*).
 - b. Other medications must be stopped while on Paxlovid, including most statins, tamsulosin. Refer to <https://www.covid19-druginteractions.org/checker>.
 - c. Dose adjustment is required for GFR 30-60 (Write for “Paxlovid Renal Dose”).
 - d. Paxlovid cannot be used in CKD 4+, or Child-Pugh C liver cirrhosis.
 - e. **Sig:** Paxlovid 2 tablets of Nirmatrelvir and 1 tablet of ritonavir to be taken at the same time daily for 5 days.
For renal dosing (GFR 30-60) one tablet of Nirmatrelvir is discarded by the pharmacy.
5. **Molnupiravir** is potentially teratogenic and requires **reliable contraception** (10 days for females, 90 days [sic!] for males).
 - a. **Sig:** Molnupiravir 800 mg orally twice daily for 5 days
6. If a patient has contraindications to Paxlovid, or Molnupiravir, they can be referred for IV therapy on the Maui Health website at mauihealth.org/covidtreatments.

The **intravenous therapy** with **Bebtelovimab** and pre-exposure prophylaxis with **Evusheld** are still limited to the hospital outpatient infusion center, which are currently being administered at Maui Memorial Medical Center. To refer patients, please go to www.mauihealth.org/covidtreatments.

If there are any questions, please contact Dr. Constantin Novoselsky at Constantin.Novoselsky@kp.org.

Prescribe non-Paxlovid COVID-19 therapy

- Amiodarone
- Apalutamide
- Bosentan
- Carbamazepine
- Cisapride
- Clopidogrel
- Clozapine
- Colchicine in patients with renal and/or hepatic impairment
- Disopyramide
- Dofetilide
- Dronedarone
- Eplerenone
- Ergot derivatives
- Flecainide
- Flibanserin
- Glecaprevir/pibrentasvir
- Ivabradine
- Lumateperone
- Lurasidone
- Mexiletine
- Phenobarbital
- Phenytoin
- Pimozide
- Propafenone
- Quinidine
- Ranolazine
- Rifampin
- Rifampin
- Rifapentine
- Rivaroxaban
- Sildenafil for pulmonary hypertension
- St. John's wort
- Tadalafil for pulmonary hypertension
- Ticagrelor
- Vorapaxar

Consider therapy modification with Paxlovid

- Alfuzosin
- Alprazolam
- Atorvastatin
- Avanafil
- Clonazepam
- Codeine
- Cyclosporine^b
- Diazepam
- Everolimus^b
- Fentanyl
- Hydrocodone
- Lomitapide
- Lovastatin
- Meperidine (pethidine)
- Midazolam (oral)
- Oxycodone
- Piroxicam
- Propoxyphene
- Rosuvastatin
- Salmeterol
- Sildenafil for erectile dysfunction
- Silodosin
- Simvastatin
- Sirolimus^b
- Suvorexant
- Tacrolimus^b
- Tadalafil for erectile dysfunction
- Tamsulosin
- Tramadol
- Triazolam
- Vardenafil

- If the patient is receiving any of these medications, withhold the medication if clinically appropriate.
- If withholding is not clinically appropriate, use an alternative concomitant medication or COVID -19 therapy.

COVID-19 Treatment Referral Form:

Scan QR or [click here](#).

